What are the differences between GnRH agonist and antagonist protocols in IVF stimulation?

What are the differences between GnRH agonist and antagonist protocols in IVF stimulation?

• A. Antagonist protocols provide long suppression of endogenous gonadotropins
• B. Agonist protocols prevent premature LH surge and are shorter with similar outcomes
• C. Agonist protocols provide long suppression of endogenous gonadotropins; antagonist protocols prevent premature LH surge, often shorter with similar outcomes and potentially lower OHSS risk in some patients
• D. There is no difference between protocols

Answer: (C)

The key idea is how GnRH control changes the timing of ovulation by managing the pituitary’s release of FSH and LH. GnRH agonist protocols cause an initial flare of gonadotropins and then produce long-lasting downregulation of GnRH receptors in the pituitary. This yields prolonged suppression of endogenous FSH/LH, so the ovaries are driven mainly by exogenous gonadotropins and the protocol tends to be longer with a more extended lead-in. GnRH antagonist protocols act differently: an antagonist blocks GnRH receptors during the follicular phase, quickly preventing the LH surge without causing long-term pituitary suppression. This allows a shorter, more flexible stimulation course, with the ability to adjust dosing as needed. Across many patients, outcomes like the number of oocytes retrieved and pregnancy rates are similar, but antagonist protocols can lower the risk of ovarian hyperstimulation syndrome in certain people, particularly when a GnRH agonist trigger is used to induce ovulation instead of hCG. So, the correct concept is that agonist protocols provide long suppression of endogenous gonadotropins, while antagonist protocols prevent premature LH surge, are often shorter, can have similar outcomes, and may carry a lower OHSS risk in some cases.

The key idea is how GnRH control changes the timing of ovulation by managing the pituitary’s release of FSH and LH. GnRH agonist protocols cause an initial flare of gonadotropins and then produce long-lasting downregulation of GnRH receptors in the pituitary. This yields prolonged suppression of endogenous FSH/LH, so the ovaries are driven mainly by exogenous gonadotropins and the protocol tends to be longer with a more extended lead-in.

GnRH antagonist protocols act differently: an antagonist blocks GnRH receptors during the follicular phase, quickly preventing the LH surge without causing long-term pituitary suppression. This allows a shorter, more flexible stimulation course, with the ability to adjust dosing as needed. Across many patients, outcomes like the number of oocytes retrieved and pregnancy rates are similar, but antagonist protocols can lower the risk of ovarian hyperstimulation syndrome in certain people, particularly when a GnRH agonist trigger is used to induce ovulation instead of hCG.

So, the correct concept is that agonist protocols provide long suppression of endogenous gonadotropins, while antagonist protocols prevent premature LH surge, are often shorter, can have similar outcomes, and may carry a lower OHSS risk in some cases.